WallStreetZenWallStreetZen

NASDAQ: KZR
Kezar Life Sciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their KZR stock forecasts and price targets.

Forecast return on equity

Is KZR forecast to generate an efficient return?

Company
-51.74%
Industry
165.03%
Market
89.46%
KZR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KZR forecast to generate an efficient return on assets?

Company
-42.58%
Industry
43.47%
KZR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KZR earnings per share forecast

What is KZR's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$7.47
Avg 2 year Forecast
-$7.03
Avg 3 year Forecast
-$7.13

KZR revenue forecast

What is KZR's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$19.3M
Avg 2 year Forecast
$20.0M
Avg 3 year Forecast
$90.2M

KZR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KZR$4.58N/AN/A
RNTX$1.51N/AN/A
TELO$1.15N/AN/A
LVTX$1.32$1.50+13.64%Hold
OKUR$2.38$32.00+1,244.54%Strong Buy
View Top Biotech Stocks

Kezar Life Sciences Stock Forecast FAQ

What is KZR's earnings growth forecast for 2025-2027?

(NASDAQ: KZR) Kezar Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.78%.

Kezar Life Sciences's earnings in 2025 is -$78,634,000.On average, 3 Wall Street analysts forecast KZR's earnings for 2025 to be -$54,598,435, with the lowest KZR earnings forecast at -$61,003,430, and the highest KZR earnings forecast at -$45,442,076. On average, 3 Wall Street analysts forecast KZR's earnings for 2026 to be -$51,335,665, with the lowest KZR earnings forecast at -$60,126,734, and the highest KZR earnings forecast at -$42,008,350.

In 2027, KZR is forecast to generate -$52,053,825 in earnings, with the lowest earnings forecast at -$64,437,156 and the highest earnings forecast at -$39,670,494.

If you're new to stock investing, here's how to buy Kezar Life Sciences stock.

What is KZR's revenue growth forecast for 2028-2030?

(NASDAQ: KZR) Kezar Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.

Kezar Life Sciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast KZR's revenue for 2028 to be $140,636,650, with the lowest KZR revenue forecast at $140,636,650, and the highest KZR revenue forecast at $140,636,650. On average, 1 Wall Street analysts forecast KZR's revenue for 2029 to be $145,896,826, with the lowest KZR revenue forecast at $145,896,826, and the highest KZR revenue forecast at $145,896,826.

In 2030, KZR is forecast to generate $658,763,986 in revenue, with the lowest revenue forecast at $658,763,986 and the highest revenue forecast at $658,763,986.

What is KZR's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: KZR) forecast ROA is -42.58%, which is lower than the forecast US Biotechnology industry average of 43.47%.

What is KZR's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: KZR) Kezar Life Sciences's current Earnings Per Share (EPS) is -$10.82. On average, analysts forecast that KZR's EPS will be -$7.47 for 2025, with the lowest EPS forecast at -$8.35, and the highest EPS forecast at -$6.22. On average, analysts forecast that KZR's EPS will be -$7.03 for 2026, with the lowest EPS forecast at -$8.23, and the highest EPS forecast at -$5.75. In 2027, KZR's EPS is forecast to hit -$7.13 (min: -$8.82, max: -$5.43).

What is KZR's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: KZR) forecast ROE is -51.74%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.